Chronic spontaneous urticaria treated with omalizumab (Xolair): A proposal of standardized tapering protocol before withdrawal to achieve the minimal effective dosage

Background: Chronic spontaneous urticaria (CSU) may represent a therapeutic challenge, although the recombinant humanized monoclonal antibody omalizumab has demonstrated a high effectiveness in the treatment of antihistamines-resistant CSU. There are no clear recommendations regarding the optimal duration of the treatment or the way to taper down the drug. The objective of our study was to describe our experience with a standardized tapering protocol of omalizumab before withdrawal.